Home › Acute Monocytic Leukemia
Acute Monocytic Leukemia clinical trials recruiting in the U.S.
8 studies for Acute Monocytic Leukemia are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04282187Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06504459Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 13, 2026 · NCT03737955Halt Aging in Survivors of Blood Cancers
Recruiting
Ages 50 and older · All sexes · Updated Jul 1, 2026 · NCT07292272211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 22, 2026 · NCT03670966Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RecruitingPhase 2
Ages 1 to 60 · All sexes · Updated Mar 12, 2026 · NCT03970096A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT06950034Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Jan 15, 2026 · NCT06429449From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.